Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012769 | Shock, NIH | 0.41 |
| D016638 | Critical Illness NIH | 0.12 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
To develop an interactive tool to screen for Elder Mistreatment (EM) in the Emergency Department (ED) to promote self-disclosure.
Description: Participation will be determined by the number of patients enrolled in VOICES. Successful enrollment of 800 older adults (N=800).
Measure: Participation Time: up to 18 monthsDescription: Usage will be determined by the number of patients enrolled in the study that complete the VOICES tool. Our target is to enroll 800 older adults (N=800).
Measure: Usage Time: up to 18 monthsDescription: Participant satisfaction will be measured using post-use satisfaction survey with a 7-point Likert response set, developed based on the focus group analysis.
Measure: Acceptability Time: up to 8 monthsDescription: Demand will be assess through examining how likely will VOICES be used by patients. To do this, the size of target population of EM victims in the ED will be measured by the % who screen positive for EM and the % who receive the Brief Negotiation Interview (BNI) portion of VOICES.
Measure: Demand Time: up to 6 monthsDescription: Implementation will be measured by understanding to what extent can VOICES be used in the ED. To do this, the degree of execution will be measured by the % of potential participants approached who consent to participate in the pilot study and of those, the number that achieve success of execution measured by # of participants who used the tool to completion. Anecdotal reasons for not completing the tool will be collected to inform process.
Measure: Implementation Time: up to 17 monthsDescription: Practicality will be assessed by observing the ease of VOICES use by patients. To do this, a series of steps will be watched to determine the efficiency of implementation measured by the average time (1) to consent & orient participants to the tool and (2) needed to complete VOICES documented by the Research Assistant; and (3) patients perceived time of VOICES as measured on post-survey. Each of these will be reported as part of the overall outcome.
Measure: Practicality Time: up to 17 monthsDescription: To understand the efficacy of VOICES in this pilot, we will look at how many participants changed their self-identification response after completing the educational component.
Measure: Efficacy of the Educational Material Time: up to 17 monthsDescription: We will look at how many patients changed their readiness to disclose after completing the Brief Negotiation Interview (BNI)
Measure: Efficacy of the Brief Negotiation Interview Time: up to 17 monthsDescription: We will explore whether self-identification impacts likelihood of self-disclosure. Effect-size estimation measured by change in the % of patients who disclose. Potential sources of bias measured by (1) sample representativeness & (2) observed group differences of participants measured by demographic data determine through t-tests and chi-square analyses.
Measure: Efficacy of Self-Identification on Self-Disclosure Time: up to 17 monthsDescription: To understand the accuracy of the VOICES tool, a preliminary evaluation of the accuracy of VOICES as a screening tool in correctly classifying EM cases that were referred to Adult Protective Services (APS). The percent correct classification will be reported.
Measure: Accuracy Time: up to 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports